Antibody Drugs

Antibody refers to a class of protective immunoglobulin produced due to the stimulation of antigens such as pathogenic bacteria and viruses and can bind specifically to antigens. The two main types of antibody are polyclonal antibody and monoclonal antibody. The former one is usually produced by different B cell clones in the body and can recognize many different epitopes of a single antigen, while the later one is generated by identical B cells and only recognize the same epitope of an antigen thus have monovalent affinity.

Antibody drugs which consist of antibody substances are prepared by antibody engineering technology based on cell and gene engineering technology. An important feature of antibody drugs is that they can be tailored making by genetic engineering and be prepared according to specific therapeutic needs. With the development of antibody genetic engineering technology, development of genetic engineered antibody as drug candidates is growing rapidly such as antibody-drug conjugates (ADC), bispecific antibody, chimeric antibody, humanized antibody, and single-domain antibody (sdAb).

Antibody-based therapeutics has entered the center stage of drug discovery and antibody drugs are currently the focus of drug research and development. In the recent years, the research and development of antibody drugs mainly focuses on oncology, neurological diseases, autoimmune diseases, cardiovascular diseases, respiratory diseases, infectious diseases, rare diseases and other disease areas.

The high specificity, affinity and efficiency of antibody is an incomparable advantage in the diagnosis and treatment of diseases compared with other types of drugs, which makes the development of antibody drugs in the global market growing strongly. However, antibody drugs are also facing many challenges. The lack of detailed research on the target function of antibody drugs may lead to severe adverse reactions and increase uncertainty of clinical trials. In addition, the problems of short half-life, poor stability and large molecular size need to be solved to ensure that drugs can be absorbed or produce expected drug effects. Moreover, the cost of antibody drugs manufacturing is also high. Therefore, antibody drug research and development still has a long way to go.

Mechanisms of action of therapeutic antibodies. Figure 1. Mechanisms of action of therapeutic antibodies. (Suzuki, M., et al., 2015)

Creative Biolabs provides powerful risk-based preclinical data verification services for antibody drug research and development to deal with data reproducibility crisis which is a big obstacle for drug research and development and may lead to failure and high risk of investment. We have extensive experience in different kinds of antibody drugs and different disease areas.

Creative Biolabs fully understands the importance of antibody drug target which should be easily accessible and has enough evidence linking to the disease. Our professional target validation service is based on comprehensive cell services and diverse animal models. Our scientific team can tailor the services to achieve your goals in a high-quality, reliable and cost-effective manner.

Drug safety and efficacy are two key factors for the success of new drug research and development. Creative Biolabs provides drug safety assessment and efficacy evaluation service to make a comprehensive assessment of your drug candidates. Our extensive experience and reliable results can help you maximize translation of efficacy into the clinic.

Creative Biolabs provides our clients with project feasibility assessment to help them make wise choices and reduce investment risk. If you are interested in further details, please contact us through on-site visits, face-to-face conversations, telephone communications, online messages and e-mail exchanges. Our customer service is available 24 hours a day, from Monday to Sunday.


  1. Suzuki, M., et al., 2015. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. Journal of toxicologic pathology, 28(3), pp. 133-139.

For Research Use Only
Let's Get Started
Contact Us

Follow us on
Copyright © 2024 Creative Biolabs. All Rights Reserved.